Activating apoptosis of tumor cells by binding a soluble form of the membrane protein TRAIL to its surface receptors DR4 and DR5 on the tumor surface shows promise as a cancer therapy, but the ligand on its own has only a minutes-long half-life and does not strongly activate the receptors.
SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two candidates for cervical and head and neck cancers caused by human papillomavirus (HPV) infection.
SML Biopharm Co. Ltd. is harnessing mRNA technology to develop novel immunotherapy-based cancer vaccines, including two candidates for cervical and head and neck cancers caused by human papillomavirus (HPV) infection.
Roche AG subsidiary Chugai Pharmaceutical Co. Ltd. and Singapore’s Gero Pte. Ltd. plan to tackle age-related diseases by collaborating to identify drug targets through Gero’s AI-driven human data-first platform.
Roche AG subsidiary Chugai Pharmaceutical Co. Ltd. and Singapore’s Gero Pte. Ltd. plan to tackle age-related diseases by collaborating to identify drug targets through Gero’s AI-driven human data-first platform.
Nearly six years after Ichnos Sciences Inc. launched operations, a subsidiary of the now-named Ichnos Glenmark Innovation (IGI) Inc. has signed with Abbvie Inc. a global licensing partnership for trispecific antibody ISB-2001 worth $1.925 billion plus royalties. ISB-2001, which targets BCMA, CD38 and CD3, is in a phase I trial for relapsed/refractory multiple myeloma and has orphan drug and fast track status in the U.S
Chugai Pharmaceutical Co. Ltd. and Gero Pte Ltd. have entered into a joint research and license agreement to develop novel therapies for age-related diseases. Chugai will create novel antibody-drug candidates for new drug targets discovered by Gero using its AI target discovery platform.
Apogee Therapeutics Inc. plans to enter a crowded atopic dermatitis market with established drugs, such as Dupixent (dupilumab, Regeneron Pharmaceuticals Inc. and Sanofi SA) and Ebglyss (lebrikizumab-lbkz, Eli Lilly and Co.), which are sold by much larger competitors. But the company thinks it can compete with its anti-IL-13 antibody, APG-777, thanks to the drug’s 77 day half-life that may allow it to be dosed only two to four times a year in the maintenance phase, compared to 13 to 26 injections per year for the established competitors.
Jasper Therapeutics Inc.’s otherwise upbeat data with subcutaneous briquilimab was hamstrung by apparent trouble with one lot of drug used in the phase Ib/II Beacon study in chronic spontaneous urticaria. Shares of the Redwood Calif.-based firm (NASDAQ:JSPR) closed July 7 at $3.04, down $3.73, or 55%.
Abion Inc. signed a potential $1.315 billion deal with an anonymous partner June 22, granting the counterparty exclusive global rights to a preclinical claudin 3-targeting monoclonal antibody, ABN-501, and the potential to license four more protein targeting antibodies.
RSS
